DMARDs – Patient Worthy

$Upadacitinib Shows Efficacy in Treating Ankylosing Spondylitis Refractory to Biologic DMARDs$

Source: https://unsplash.com/photos/ZHys6xN7sUE

Upadacitinib Shows Efficacy in Treating Ankylosing Spondylitis Refractory to Biologic DMARDs

Post author:Jessica Lynn
Post published:September 13, 2022
Post category:Ankylosing Spondylitis

Many patients with ankylosing spondylitis (AS) could be treated with biologics – in particular, biologic disease-modifying antirheumatic drugs (DMARDs). However, this line of treatment is not efficacious nor well-tolerated…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Upadacitinib Shows Efficacy in Treating Ankylosing Spondylitis Refractory to Biologic DMARDs

Why Your Voice in Research Matters: Groundbreaking Studies are Changing What's Possible

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Let’s Work Together!

Keep Up to Date

Learn More